Hold Sun Pharma, says Sharmila Joshi

Sharmila Joshi of sharmilajoshi.com told CNBC-TV18, "In Sun Pharmaceutical Industries a lot of the negatives are now in the price. Post their Ranbaxy acquisition as well as this whole USFDA onslaught that we have seen on the entire Indian pharma space, we have seen a lot of the stocks correct by the 20-25 percent."

"It is an industry-wide phenomena, sector-wise that is what I am trying to say rather than stock specific though there have been stock specific negatives and big negatives at that for Sun Pharma. But my sense is that they are now in the price and at this price, I do not think that is a price that you should look to be exiting at especially if you have a 2-3 year horizon, I am sure you will make better money than the current price. So I would say stay put," she added.